Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study (Q33432228)

26 July 2017

title

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study (English)

1 reference

multicenter clinical trial

26 July 2017

main subject

0 references

0 references

1 reference

chronic lymphocytic leukemia

1 reference

inferred from title

author

Clemens-Martin Wendtner

object named as

Clemens-Martin Wendtner

1 reference

26 July 2017

Barbara Eichhorst

0 references

Stephan Stilgenbauer

object named as

Stephan Stilgenbauer

0 references

Andrew W Roberts

0 references

Wojciech Jurczak

0 references

William G Wierda

1 reference

26 July 2017

Michael Hallek

1 reference

26 July 2017

Johannes Schetelig

1 reference

26 July 2017

Steven Coutre

1 reference

26 July 2017

Talha Munir

1 reference

26 July 2017

Stephen P Mulligan

1 reference

26 July 2017

Sebastian Böttcher

1 reference

26 July 2017

Monali Desai

1 reference

26 July 2017

Brenda Chyla

1 reference

26 July 2017

Rod Humerickhouse

1 reference

26 July 2017

John F Seymour

1 reference

26 July 2017

Soham D Puvvada

1 reference

26 July 2017

Mehrdad Mobasher

1 reference

26 July 2017

Ming Zhu

1 reference

26 July 2017

Maria Verdugo

1 reference

26 July 2017

Sari Heitner Enschede

1 reference

26 July 2017

Elisa Cerri

1 reference

26 July 2017

Gary Gordon

1 reference

26 July 2017

language of work or name

1 reference

10 May 2016

1 reference

Lancet Oncology Commission

26 July 2017

published in

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

768-778

1 reference

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Mutations driving CLL and their evolution in progression and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Molecular pathogenesis of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

The clinical safety of ibrutinib in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930019-5

7 January 2021

10.1016/S1470-2045(16)30019-5

Identifiers

DOI

1 reference

26 July 2017

1 reference